With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

Moderna (MRNA) stock contnues to tumble as J.P. Morgan and Jefferies downgrade the biotech following updates at the company's ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.